View Older Stories

Jan 15, 2026 04:22AM Goldman Sachs: 'we view DNLI as attractive given the aforementioned dynamics'

Jan 7, 2026 12:41AM UBS Assumes Denali Therapeutics Inc. (DNLI) at Buy

Jan 6, 2026 08:04AM Denali Therapeutics outlines 2026 milestones including Hunter syndrome launch

Dec 30, 2025 09:57AM Jefferies on Denali (DNLI): 'Net-net, we remain 70-80%+ confident in an FDA approval by the April 5, 2026 PDUFA date'

Dec 9, 2025 04:28PM After-hours movers: GE Vernova, AeroVironment, Cracker Barrel, GameStop and more

Dec 5, 2025 07:32AM Denali Therapeutics (DNLI) Confident of 2026 Approval for tivi/DNL310 - Stifel

Dec 4, 2025 07:02AM Denali Therapeutics secures $275 million royalty deal with Royalty Pharma

Nov 17, 2025 09:28AM Stifel Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)

Nov 6, 2025 06:48PM Denali Therapeutics Inc. (DNLI) Tops Q3 EPS by 1c

Nov 6, 2025 04:00PM Denali Therapeutics names new board member, chief medical officer

Oct 15, 2025 07:25AM H.C. Wainwright Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)

Oct 14, 2025 07:05AM Stifel Sees Accelerated Approval for Denali Therapeutics Inc.'s (DNLI) DNL310

Oct 13, 2025 04:01PM FDA extends review timeline for Denali's Hunter syndrome treatment

Sep 8, 2025 06:55AM Cantor Fitzgerald Reiterates Overweight Rating on Denali Therapeutics Inc. (DNLI)

Aug 11, 2025 04:03PM Denali Therapeutics Inc. (DNLI) Misses Q2 EPS by 1c

Aug 7, 2025 05:38AM BTIG Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)

Jul 7, 2025 10:45AM William Blair Reiterates Outperform Rating on Denali Therapeutics Inc. (DNLI) 'Remains undervalued and de-risked'

Jul 7, 2025 10:13AM Stifel Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)

Jul 7, 2025 08:03AM FDA accepts Denali Therapeutics' (DNLI) hunter syndrome drug application

Jun 23, 2025 03:21PM Oppenheimer Reiterates Outperform Rating on Denali Therapeutics Inc. (DNLI)

Jun 5, 2025 12:44PM FDA Cell and Gene Therapy Roundtable 'bullish for the space' - Stifel

May 27, 2025 09:47AM Stifel Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)

May 8, 2025 06:44AM Denali Therapeutics Inc. (DNLI) PT Lowered to $32 at H.C. Wainwright

May 6, 2025 05:38PM Denali Therapeutics Inc. (DNLI) Misses Q1 EPS by 8c

Apr 2, 2025 08:04AM Denali Therapeutics (DNLI) Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on

Mar 17, 2025 07:06AM Cantor Fitzgerald says 15% of biotech companies down 40% or more

Mar 7, 2025 08:12AM Morgan Stanley Starts Denali Therapeutics Inc. (DNLI) at Overweight

Feb 28, 2025 07:11AM Denali Therapeutics Inc. (DNLI) PT Lowered to $80 at H.C. Wainwright

Feb 27, 2025 05:02PM Denali Therapeutics Inc. (DNLI) Tops Q4 EPS by 17c

Feb 27, 2025 04:20PM Denali Therapeutics (DNLI) Files Mixed Shelf

Feb 11, 2025 04:15AM Deutsche Bank Starts Denali Therapeutics Inc. (DNLI) at Buy

Feb 10, 2025 05:32AM Stifel Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)

Feb 6, 2025 11:42AM Denali Therapeutics (DNLI) Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

Jan 8, 2025 09:34AM Stifel Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)

Jan 8, 2025 08:04AM Denali Therapeutics (DNLI) Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome

Jan 7, 2025 08:51AM Jefferies on Denali Therapeutics Inc. (DNLI): 'should be a buying opportunity for a better set up for the rest of the year'

Jan 7, 2025 06:51AM Denali Therapeutics Inc. (DNLI) PT Lowered to $87 at H.C. Wainwright

Jan 7, 2025 05:23AM Denali Therapeutics Inc. (DNLI) PT Lowered to $30 at BofA Securities

Jan 7, 2025 05:03AM Baird Starts Denali Therapeutics Inc. (DNLI) at Outperform

Jan 6, 2025 04:42PM After-hours movers: Ulta Beauty, Inari Medical, Meta Platforms and more

Jan 6, 2025 04:31PM Denali Therapeutics' (DNLI) Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial Did Not Meet Endpoints

Dec 16, 2024 04:48AM Stifel Upgrades Denali Therapeutics Inc. (DNLI) to Buy

Nov 12, 2024 01:05PM Denali Therapeutics Inc. (DNLI) PT Raised to $34 at BofA Securities

Nov 1, 2024 05:46AM Denali Therapeutics Inc. (DNLI) PT Raised to $45 at Jefferies

Oct 14, 2024 06:04AM BTIG Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)

Oct 11, 2024 08:45AM TD Cowen Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)

Sep 4, 2024 05:26AM Denali Therapeutics Inc. (DNLI) PT Raised to $29 at BofA Securities

Sep 3, 2024 11:58AM B.Riley Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)

Sep 3, 2024 11:46AM Goldman Sachs Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)

Sep 3, 2024 10:22AM Stifel Reiterates Hold Rating on Denali Therapeutics Inc. (DNLI)

View Older Stories